Health
Entresto’s effect ‘unclear’ in advanced chronic heart failure: study – Korea Biomedical Review
Novartis’ Entresto (ingredient: sacubitril/valsartan), an angiotensin receptor-neprilysin inhibitor (ARNI), has become the standard…
Novartis’ Entresto (ingredient: sacubitril/valsartan), an angiotensin receptor-neprilysin inhibitor (ARNI), has become the standard therapy for heart failure with reduced ejection fraction (HFrEF).
However, a recent study showed that the treatment did not…
Continue Reading
-
General23 hours agoCampers evacuated, residents on alert as Moreton Island bushfire intensifies
-
General21 hours agoHundreds attend justice march for Kaiden Morgan-Johnston in Morwell
-
Noosa News22 hours agoAlleged Gold Coast conman exposed: elderly woman’s life savings vanish in shocking scam
-
Noosa News22 hours agoHow Roosters star Eliza Lopamaua found her way to NRLW